Skip to main content

Advertisement

SpringerLink
Log in

Dasatinib promotes ATRA-induced differentiation of AML cells

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

References

  1. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658–6661.

    Article  CAS  Google Scholar 

  2. Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG et al. Association between imatinib-resistant BCR–ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008; 100: 926–939.

    Article  CAS  Google Scholar 

  3. Vandyke K, Dewar AL, Farrugia AN, Fitter S, To LB, Hughes TP et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009; 23: 994–997.

    Article  CAS  Google Scholar 

  4. Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ . Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 2009; 23: 590–594.

    Article  CAS  Google Scholar 

  5. Gratacap MP, Martin V, Valera MC, Allart S, Garcia C, Sie P et al. The new tyrosine-kinase inhibitor and anti-cancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009; 114: 1884–1892.

    Article  CAS  Google Scholar 

  6. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R . Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366–1377.

    Article  CAS  Google Scholar 

  7. Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP . Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008; 111: 4415–4416.

    Article  CAS  Google Scholar 

  8. Miranda MB, Redner RL, Johnson DE . Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiation. Mol Cancer Ther 2007; 6: 3081–3090.

    Article  CAS  Google Scholar 

  9. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR . Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 2005; 106: 2841–2848.

    Article  CAS  Google Scholar 

  10. Miranda MB, Duan R, Thomas SM, Grandis JR, Redner RL, Jones JE et al. Gefitinib potentiates myeloid cell differentiation by ATRA. Leukemia 2008; 22: 1624–1627.

    Article  CAS  Google Scholar 

  11. Boehrer S, Ades L, Braun T, Galluzzi L, Grosjean J, Fabre C et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008; 111: 2170–2180.

    Article  CAS  Google Scholar 

  12. Chan G, Pilichowska M . Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. Blood 2007; 110: 1079–1080.

    Article  CAS  Google Scholar 

  13. Pitini V, Arrigo C, Altavilla G . Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer. J Clin Oncol 2008; 26: 3645–3646.

    Article  Google Scholar 

  14. Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Recher C . A critical role for Lyn in acute myeloid leukemia. Blood 2008; 111: 2269–2279.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Bristol-Myers Squibb (New York, NY) for providing dasatinib. This work was supported by National Institutes of Health Grant R01 CA108904.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Pittsburgh and the University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

    P L Kropf, L Wang, Y Zang, R L Redner & D E Johnson

  2. Department of Pharmacology, University of Pittsburgh, Pittsburgh, PA, USA

    D E Johnson

Authors
  1. P L Kropf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Zang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R L Redner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D E Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D E Johnson.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kropf, P., Wang, L., Zang, Y. et al. Dasatinib promotes ATRA-induced differentiation of AML cells. Leukemia 24, 663–665 (2010). https://doi.org/10.1038/leu.2009.267

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.267

  • Springer Nature Limited

This article is cited by

Search

Navigation